Literature DB >> 9050994

Derivatives of activated H-ras lacking C-terminal lipid modifications retain transforming ability if targeted to the correct subcellular location.

K C Hart1, D J Donoghue.   

Abstract

To examine the ability of ras to activate signal transduction pathways in the absence of lipid modifications, fusion proteins were constructed that target rasWT or activated ras61L to cellular membranes as integral membrane proteins, using the first transmembrane domain of the E1 protein of avian infectious bronchitis virus (IBV), which contains a cis-Golgi targeting signal. Golgi-targeted derivatives of activated ras were completely inactive in transformation assays. However, when examined in focus formation assays, transformation of NIH3T3 cells were seen with derivatives of ras61L containing a mutated E1 targeting sequence that results in plasma membrane localization. Removal of the lipid modification sites in and upstream of the CAAX motif did not abrogate the transforming activity of plasma membrane-localized ras61L derivatives, indicating that these lipid modifications are not essential for ras activity, as long as the protein is correctly localized to the plasma membrane. Interestingly, the activity of integral membrane versions of ras61L was strictly dependent on a minimum distance between the transmembrane domain anchor region and the coding sequence of ras. Derivatives with only a 3-amino acid linker were inactive, while linkers of either 11- or 22-amino acids were sufficient to restore transforming activity. These results demonstrate that: (1) activated ras targeted to Golgi membranes is unable to cause transformation; (2) lipid modifications at the C-terminus are not required for the transforming activity of plasma membrane-anchored ras61L derivatives, and serve primarily a targeting function; (3) a transmembrane domain can effectively substitute for C-terminal modifications that would normally target ras to the inner surface of the plasma membrane, indicating that ras61L does not need to reversibly dissociate from the membrane as might be allowed by the normal lipidation; and (4) in order to function properly, there exists a critical distance that the ras protein must reside from the plasma membrane.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9050994      PMCID: PMC7100284          DOI: 10.1038/sj.onc.1200908

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  Distinct utilization of effectors and biological outcomes resulting from site-specific Ras activation: Ras functions in lipid rafts and Golgi complex are dispensable for proliferation and transformation.

Authors:  David Matallanas; Victoria Sanz-Moreno; Imanol Arozarena; Fernando Calvo; Lorena Agudo-Ibáñez; Eugenio Santos; María T Berciano; Piero Crespo
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

2.  The RafC1 cysteine-rich domain contains multiple distinct regulatory epitopes which control Ras-dependent Raf activation.

Authors:  M Daub; J Jöckel; T Quack; C K Weber; F Schmitz; U R Rapp; A Wittinghofer; C Block
Journal:  Mol Cell Biol       Date:  1998-11       Impact factor: 4.272

3.  Ras, an actor on many stages: posttranslational modifications, localization, and site-specified events.

Authors:  Imanol Arozarena; Fernando Calvo; Piero Crespo
Journal:  Genes Cancer       Date:  2011-03

4.  Speedy: a novel cell cycle regulator of the G2/M transition.

Authors:  J L Lenormand; R W Dellinger; K E Knudsen; S Subramani; D J Donoghue
Journal:  EMBO J       Date:  1999-04-01       Impact factor: 11.598

5.  Expression of a phosphorylated substrate domain of p130Cas promotes PyMT-induced c-Src-dependent murine breast cancer progression.

Authors:  Yingshe Zhao; Joerg Kumbrink; Bor-Tyh Lin; Amy H Bouton; Shi Yang; Paul A Toselli; Kathrin H Kirsch
Journal:  Carcinogenesis       Date:  2013-07-03       Impact factor: 4.944

Review 6.  The interplay between cell signalling and the mevalonate pathway in cancer.

Authors:  Peter J Mullen; Rosemary Yu; Joseph Longo; Michael C Archer; Linda Z Penn
Journal:  Nat Rev Cancer       Date:  2016-08-26       Impact factor: 60.716

7.  Relationship of SNP rs2645429 in Farnesyl-Diphosphate Farnesyltransferase 1 Gene Promoter with Susceptibility to Lung Cancer.

Authors:  Mehdi Dehghani; Zahra Samani; Hassan Abidi; Leila Manzouri; Reza Mahmoudi; Saeed Hosseini Teshnizi; Mohsen Nikseresht
Journal:  Int J Genomics       Date:  2018-03-22       Impact factor: 2.326

8.  RAS at the Golgi antagonizes malignant transformation through PTPRκ-mediated inhibition of ERK activation.

Authors:  Berta Casar; Andrew P Badrock; Iñaki Jiménez; Imanol Arozarena; Paula Colón-Bolea; L Francisco Lorenzo-Martín; Irene Barinaga-Rementería; Jorge Barriuso; Vincenzo Cappitelli; Daniel J Donoghue; Xosé R Bustelo; Adam Hurlstone; Piero Crespo
Journal:  Nat Commun       Date:  2018-09-05       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.